We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Significant clinical worsening after natalizumab withdrawal: Predictive factors.
- Authors
Vidal-Jordana, A; Tintoré, M; Tur, C; Pérez-Miralles, F; Auger, C; Río, J; Nos, C; Arrambide, G; Comabella, M; Galán, I; Castilló, J; Sastre-Garriga, J; Rovira, A; Montalban, X
- Abstract
We aimed to single out multiple sclerosis (MS) cases with poor outcome after natalizumab withdrawal and to identify predictive variables. We ascertained 47 withdrawals, and compared their pre- and post-natalizumab periods. We objectively defined significant clinical worsening after natalizumab withdrawal as a 2-step increase in Expanded Disability Status Scale (EDSS). We performed regression models. As a group, post-natalizumab annualized relapse rate (ARR) was lower in the post-natalizumab period, and there were no differences in the mean number of gadolinium (Gd)-enhancing lesions between pre- and post-natalizumab magnetic resonance imaging (MRI). Corticosteroid treatment did not change the outcomes. Eight patients (19%) presented significant clinical worsening after natalizumab withdrawal, which was predicted by a higher baseline EDSS and a 1-step EDSS increase while on natalizumab.
- Subjects
DRUG withdrawal symptoms; MAGNETIC resonance imaging; MULTIPLE sclerosis; NATALIZUMAB; PREDICTIVE control systems
- Publication
Multiple Sclerosis Journal, 2015, Vol 21, Issue 6, p780
- ISSN
1352-4585
- Publication type
Article
- DOI
10.1177/1352458514549401